Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy.

We evaluated acute toxicity and disease control in 42 patients receiving thoracic radiotherapy with concurrent KRAS G12C inhibitors. Toxicity included 13 grade 2 events (31%) and one grade 3 pneumonitis. There were no significant differences in toxicity between patients who held versus continued inhibitors during radiotherapy. The estimated cumulative incidence of local failure at 6 months was 5%.